Allucent, a global specialty CRO serving small and mid-sized biopharma, announced new therapeutic strategy leaders across its Allucent Centers of Expertise (ACEs), including oncology, neuroscience, cardiometabolic diseases, and immunology & inflammation. Allucent also announced a head of advanced therapeutics spanning rare disease and cell and gene therapy (CGT) programs.

These new roles aim to support emerging biopharma innovation across complex therapeutic areas and advanced modalities. By combining deep therapeutic expertise with integrated strategy and execution the company aims to help sponsors navigate complexity and move programs forward.

Brant Nicks  

Brant Nicks joins as therapeutic strategy head, hematology and oncology, bringing more than 30 years of experience leading global oncology programs across CRO and biotech, spanning first-in-human through late-phase development and supporting innovative modalities and regulatory approvals.

Roberta Anderson  

Roberta Anderson joins as therapeutic strategy head, neuroscience, with nearly 30 years of CNS clinical development experience across multiple indications and a strong track record guiding programs through complex regulatory pathways, including IND submissions and global approvals.

Additionally, Mila Grieg, MD, PhD, has been appointed as therapeutic strategy head for cardiometabolic and immunology & inflammation, and Maria-Cruz Morillo, M.S. Pharmacy, has been named head of advanced therapeutics, supporting rare disease and CGT programs.

“These appointments reflect the increasing complexity of drug development and the need for a more specialized, integrated approach,” said Paula Brown Stafford, CEO of Allucent. “Small and mid-sized biopharma are advancing complex science but are often met with fragmented models that separate strategy from execution. Our ACEs are designed to change that, embedding scientific, regulatory, and operational leadership within each therapeutic area to streamline decision-making and accelerate execution.”

ACEs focus on therapeutic areas and modalities with high development demands, including oncology, neuroscience, infectious diseases, cardiometabolic diseases, and immunology & inflammation, and rare diseases and CGT. ACE teams work to enhance study design, strengthen feasibility, and streamline trial delivery.